RxDoctor Payments DataLook up a doctor →

John Allen, MD

Hematology & Oncology · Oxford, MSNPI 1417275652

Payments from drug & device makers

$21,175in general payments, 2019–2025

Across 1,135 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Exelixis Inc.$2K
  • Merck$1K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$1K
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$20,25696%
  • Education$9194%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis109$1,780
Exelixis Inc.25$1,722
Merck69$1,348
Johnson & Johnson(2 entities)72$1,218
E.r. Squibb & Sons, L.L.C.91$1,185
Pfizer78$1,108
AstraZeneca63$1,078
Amgen50$846
Gilead(2 entities)38$845
Takeda Pharmaceuticals U.S.A., Inc.31$729
Bristol Myers Squibb37$669
Lilly USA, LLC35$630
Genentech USA, Inc.32$609
Astellas Pharma US Inc25$598
AbbVie24$579
Incyte Corporation34$569
GSK30$501
Seagen Inc.28$426
Pharmacyclics LLC, An Abbvie Company24$380
Eisai Inc.24$373
Regeneron Healthcare Solutions, Inc.13$285
Bayer14$237
Beigene USA, Inc.12$226
Jazz Pharmaceuticals Inc.9$219
Rigel Pharmaceuticals, Inc.14$215
Sanofi10$210
Tersera Therapeutics LLC9$194
AVEO Pharmaceuticals, Inc.9$176
Daiichi Sankyo Inc.10$171
Pharmacosmos Therapeutics Inc.7$140
Karyopharm Therapeutics Inc.2$134
Dendreon Pharmaceuticals LLC5$115
Puma Biotechnology, Inc.9$114
Array Biopharma Inc6$110
AMAG Pharmaceuticals, Inc.8$106
G1 Therapeutics, Inc.6$91
Beone Medicines USA, Inc.4$91
Mirati Therapeutics, Inc.6$90
Coherus Oncology, Inc.6$88
EMD Serono, Inc.6$85
Adaptive Biotechnologies Corporation3$70
Tempus AI, Inc3$63
Sobi, Inc3$58
Secura Bio, Inc.5$55
Taiho Oncology, Inc.3$53
Acceleron Pharma, Inc.3$46
Tesaro, Inc.2$41
Kyowa Kirin, Inc.2$41
Blueprint Medicines Corporation2$41
Boehringer Ingelheim2$32
Foundation Medicine, Inc.2$30
Agios Pharmaceuticals, Inc.2$29
Clovis Oncology, Inc.2$26
Deciphera Pharmaceuticals Inc.1$25
Springworks Therapeutics, Inc.1$24
Stemline Therapeutics Inc.1$23
Myriad Genetic Laboratories, Inc.2$23
Recordati_rare_diseases_inc.1$23
Legend Biotech USA Inc.1$21
Dova Pharmaceuticals1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,175 in reported general payments places this provider in the 55th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$161,596
Medicare patients
592
Services billed
2,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LonsurfTrifluridine/Tipiracil Hcl52$539,187
Lenalidomide28$499,455
PomalystPomalidomide16$371,892
CabometyxCabozantinib S-Malate13$329,427
RevlimidLenalidomide17$287,675
IbrancePalbociclib18$266,267
BrukinsaZanubrutinib22$254,713
TasignaNilotinib Hcl11$207,229
ErleadaApalutamide11$154,197
VenclextaVenetoclax17$123,122
Abiraterone Acetate44$108,789
KisqaliRibociclib Succinate16$101,867
PromactaEltrombopag Olamine13$89,918
EliquisApixaban64$38,630
XareltoRivaroxaban37$20,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Taiho Oncology, Inc.Lonsurf$53$539,18752 claims
NovartisTasigna, Kisqali, Promacta$1,780$399,01540 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$1,185$371,89216 claims
Exelixis Inc.Cabometyx$1,722$329,42713 claims
PfizerIbrance, Eliquis$1,108$304,89782 claims
Bristol Myers SquibbRevlimid$669$287,67517 claims
Beigene USA, Inc.Brukinsa$226$254,71322 claims
Johnson & JohnsonErleada, Xarelto$1,218$174,43648 claims
AbbVieVenclexta$579$123,12217 claims
Lilly USA, LLCOlanzapine$630$49442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →